Saudi Journal of Kidney Diseases and Transplantation

ORIGINAL ARTICLE
Year
: 2009  |  Volume : 20  |  Issue : 5  |  Page : 770--774

Modifying cyclosporine associated renal allograft dysfunction


N Mohapatra1, AV Vanikar1, RD Patel1, HL Trivedi2 
1 Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr. H.L. Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India
2 Department of Nephrology and Transplantation Medicine G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr. H.L. Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India

Correspondence Address:
A V Vanikar
Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G. R.. Doshi and K. M. Mehta Institute of Kidney Diseases & Research Centre (IKDRC)- Dr. H. L. Trivedi Institute of Transplantation Sciences (ITS) Civil Hospital Campus, Asarwa, Ahmedabad 380016, Gujarat
India

Transplantation is accepted therapy for chronic kidney disease. However the essential immuno­suppressive agents for graft survival have their own side-effects. Renal biopsy is a reliable tool for diagnosing cyclosporine (CsA) nephrotoxicity. To present our observations on CsA toxicity in renal allograft biopsies, we studied prospectively 207 renal allograft biopsies performed for graft dysfunction as per Ahmedabad Tole­rance Induction Protocol (ATIP) and compared them to 50 controls from January to October 2007. The ATIP comprised donor specific leucocyte infusions, low dose target specific irradiation; non-myeloablative condi­tioning with Anti-T ± B cell antibodies followed by intraportal administration of cultured donor bone marrow (BM) ± adipose tissue derived mesenchymal stem cells. Renal transplantation was performed following nega­tive lymphocytotoxicity cross-matching. The post-transplant immunosuppressive agents included CsA 2.5 ± 0.5 mg/kg BW/day and prednisone 0.2 mg/kg BW/day. The controls were transplanted using standard triple immunosuppressive agents including CsA 5 ± 1 mg/Kg BW/day, prednisone 0.6 mg/kg BW/day, and MMF/ Azathioprine. The Institutional Review Board approved the ATIP. The biopsies were categorized into 2 groups; group A (N=97): performed < 6 months, group B (N= 160), > 6 months posttransplant. Acute CsA toxicity was observed in group A: 2.5% ATIP and 11.1% controls; group B: 16.2% ATIP and 8.8% controls. Chronic CsA toxicity was observed in group B: 10.8 % ATIP and 17.6 % controls. Acute toxicity was more in the ATIP, while chronic toxicity was more in the controls. CsA doses were reduced post-biopsy and resulted in improved graft function evaluated by serum creatinine. We conclude that CsA nephrotoxicity evaluated by allograft biopsy resulted in allograft function recovery by decreasing the cyclosporine dose, and the ATIP decreased the incidence of CsA nephrotoxicity.


How to cite this article:
Mohapatra N, Vanikar A V, Patel R D, Trivedi H L. Modifying cyclosporine associated renal allograft dysfunction.Saudi J Kidney Dis Transpl 2009;20:770-774


How to cite this URL:
Mohapatra N, Vanikar A V, Patel R D, Trivedi H L. Modifying cyclosporine associated renal allograft dysfunction. Saudi J Kidney Dis Transpl [serial online] 2009 [cited 2022 May 27 ];20:770-774
Available from: https://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=5;spage=770;epage=774;aulast=Mohapatra;type=0